Business context and reporting period
Filing identity mismatch: The supplied filing is for AFH Acquisition X, Inc., not Bone Biologics Corp. It is a Form 10-K for the fiscal year ended October 31, 2013; it does not provide standalone fourth-quarter results.
AFH Acquisition X describes itself as a development-stage blank-check/shell company formed to pursue a merger or acquisition. It had no operating business, no revenues since inception, and no identified target or definitive transaction at the filing date. Its common stock was not publicly listed.
Financial results and liquidity
| Metric | FY 2013 | FY 2012 | At October 31, 2013 |
|---|---|---|---|
| Revenue | $0 | $0 | — |
| Net loss | $5,206 | $5,631 | Accumulated deficit: $64,805 |
| Operating cash flow | $(6,116) | $(6,057) | Cash: $380 |
| Financing cash flow | $5,996 | $6,557 | Current liabilities: $40,185 |
| Total assets | — | — | $380 |
Liabilities comprised $3,584 of accrued expenses and $36,601 due to the parent, AFH Holding & Advisory, LLC; the parent advances have no repayment terms. Stockholders’ deficit was $39,805. The filing reports no debt beyond these liabilities, but does not provide a clear interest-bearing debt balance. Margins are not meaningful because the company had no revenue.
Material changes versus the prior comparable period
Net loss narrowed by $425, from $5,631 to $5,206. Cash declined from $500 to $380, while total liabilities increased from $35,099 to $40,185, primarily reflecting an increase in amounts due to the parent. Operating cash outflow was broadly similar year over year.
Outlook, risks, contingencies, and unusual items
- Management planned to continue seeking an acquisition and expected to fund reporting and search costs from treasury funds, deferred service-provider fees, and further loans or investments. The company said it could not assure that it could meet cash needs for the next 12 months.
- The auditor and management disclosed substantial doubt about the company’s ability to continue as a going concern. Continuation depends on raising capital or completing a business combination; the financial statements include no adjustments for a possible failure to continue.
- AFH Acquisition X stated that it depends on related parties for funding and had limited resources to evaluate prospective targets. Any combination could involve a financially unstable or early-stage business, significant risk, and substantial dilution to existing holders.
- The filing reports that EFP Rotenberg resigned in November 2013 and Anton & Chia was engaged in January 2014. The new auditor issued an unqualified opinion on the financial statements while emphasizing the going-concern uncertainty; the auditor did not opine on internal-control effectiveness.
- Litigation described in the filing concerns the parent/adviser and its sole officer, rather than being identified as litigation against AFH Acquisition X itself. The filing describes ongoing Emmaus claims against the parent/adviser and Banner Bank judgment-enforcement proceedings involving the officer; investors should verify any potential effects on the company or its controlling parties.
Most important facts for investors to verify
- Confirm the issuer: this filing names AFH Acquisition X, Inc., not Bone Biologics Corp.
- Verify the company’s current funding arrangements and whether parent advances or other financing remain available.
- Review the going-concern disclosure, $380 cash balance, and $40,185 liabilities against subsequent filings.
- Check for any later acquisition, merger, change of control, or securities issuance that could materially dilute the reported 5,000,000 shares outstanding.
- Assess whether the disclosed auditor change and litigation involving the parent/adviser or sole officer have produced later developments relevant to the issuer.